Mon, May 29, 2017
Sun Pharma's fourth quarter results have been disappointing. The company said that pricing pressure in its US generic operation will continue for more time. Analysts, in the meantime, have begun downgrading the stock.
More >
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
